8.70
前日終値:
$8.86
開ける:
$8.81
24時間の取引高:
81,153
Relative Volume:
0.29
時価総額:
$583.37M
収益:
$555.06M
当期純損益:
$-39.48M
株価収益率:
-14.50
EPS:
-0.6
ネットキャッシュフロー:
$29.05M
1週間 パフォーマンス:
+3.19%
1か月 パフォーマンス:
+8.17%
6か月 パフォーマンス:
+20.05%
1年 パフォーマンス:
-19.07%
Bioventus Inc Stock (BVS) Company Profile
名前
Bioventus Inc
セクター
電話
(919) 474-6700
住所
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc
|
8.71 | 593.41M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
110.09 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
342.26 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.89 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.85 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.50 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-09 | 開始されました | Barrington Research | Outperform |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-07 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | アップグレード | Craig Hallum | Hold → Buy |
| 2022-11-22 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-11-09 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 開始されました | Craig Hallum | Buy |
| 2021-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2021-11-10 | 再開されました | JP Morgan | Overweight |
| 2021-07-01 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-08 | 開始されました | Canaccord Genuity | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | JP Morgan | Overweight |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioventus Inc (BVS) 最新ニュース
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com South Africa
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Shares Rise After Analyst Upgrade - National Today
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges By Investing.com - Investing.com South Africa
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus shares jump 7.6% on fourth-quarter earnings beat By Investing.com - Investing.com Canada
Bioventus shares jump 7.6% on fourth-quarter earnings beat - Investing.com Australia
Bioventus beats Q4 estimates, guides 2026 revenue in line By Investing.com - Investing.com Australia
Bioventus Q4 2025 Earnings Call Transcript - MarketBeat
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS - TradingView
Bioventus (BVS) Exceeds Q4 Revenue Expectations, Eyes Future Gro - GuruFocus
Bioventus Q4 and Full Year 2025 Financial Results - TradingView
BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative
Bioventus beats Q4 estimates, guides 2026 revenue in line - Investing.com India
Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bioventus Q4 Earnings Assessment - Benzinga
Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions - TradingView
Bioventus Earnings Report: Q4 Overview - Benzinga
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Preview: Bioventus's Earnings - Benzinga
Bioventus Inc. $BVS Shares Bought by Royce & Associates LP - MarketBeat
Bioventus (BVS) versus Its Peers Critical Comparison - Defense World
Bioventus (NYSE:BVS) Stock Price Down 0.1%Should You Sell? - MarketBeat
Bioventus Inc. (BVS) Stock Analysis: Unpacking A 63.66% Potential Upside - DirectorsTalk Interviews
Reviewing Bioventus (BVS) and Its Peers - Defense World
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - AOL.com
BVS | Bioventus Inc. Class A FinancialsIncome Statement - Quiver Quantitative
Bioventus Inc (BVS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):